Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

XZO vs LMRI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XZO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

XZO Overall Winner 6-Pillar Tally: XZO 5 – 0 LMRI (1 Tie) Matrix Metrics: XZO 9 – 1 LMRI

As of Nov 20, 2026, Exzeo Group, Inc. (XZO) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XZO carries a Unified Composite Score of 47.7/100 (HOLD) at $14.72 (12.5x Forward P/E, 50.4% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XZO vs LMRI
XZO US Equity Head-to-Head Winner
Exzeo Group, Inc.
Services-Prepackaged Software
$14.72
-3.03% 1D
Market Cap $1.4B
TTM Revenue $233M
Forward P/E 12.5x
Beta / 30D Vol 1.08β · 60% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 39.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.6 · SMA20: $16.67 · SMA50: $16.21
LMRI US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.22β · 85% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 63
RSI-14: 62.5 · SMA20: $13.28 · SMA50: $11.73

6-Pillar Scorecard Institutional Category Breakdown (XZO 5 – 0 LMRI)

Columns: Metric · XZO · LMRI
1. Valuation Multiples XZO
Forward P/E 12.5x N/M
Trailing P/E 15.5x N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x N/M
2. Growth & Scale XZO
Revenue Growth (YoY) +4.0% N/A
Earnings Growth (YoY) -0.7% N/A
TTM Revenue (USD) $233M N/A
Market Cap $1.4B N/A
3. Profitability & Quality XZO
Gross Margin 100.0% N/A
Operating Margin 50.4% N/A
Net Profit Margin 37.8% N/A
Return on Equity (ROE) 46.7% N/A
4. Balance Sheet & Cash Flow XZO
Cash Generation (TTM) $104M N/A
Cash Flow Margin 44.5% N/A
Net Cash / Leverage $224M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat XZO
OpEx & R&D Intensity 49.6% of Rev ($115M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance - Diversified Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XZO (9) vs LMRI (1)
Institutional Metric XZO LMRI Criterion Row Edge
Market Capitalization
Scale
$1.4B N/A Larger Scale XZO
Trailing P/E Ratio
Valuation
15.5x N/M Lower Multiple XZO
Forward P/E Ratio
Valuation
12.5x N/M Lower Multiple XZO
Revenue Growth (YoY)
Growth
+4.0% N/A Higher Growth XZO
Operating Margin (TTM)
Profitability
50.4% N/A Higher Margin XZO
Net Profit Margin
Profitability
37.8% N/A Higher Margin XZO
Return on Equity (ROE)
Capital Efficiency
46.7% N/A Higher ROE XZO
52-Week Range Position
Momentum
19% ($12–$25) 60% ($6–$19) Stronger Trend LMRI
Beta / 30D Volatility
Risk Regime
1.08β · 60% Vol 1.22β · 85% Vol Lower Realized Risk XZO
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 32.1 / 100 (SELL) Higher Composite XZO
Trailing 12M Revenue (USD)
Operating Scale
$233M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$104M ($224M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMRI +44.36 pp
XZO: -13.41% · LMRI: +30.95%
3M Horizon LMRI +36.03 pp
XZO: -15.69% · LMRI: +20.34%
6M Horizon LMRI +64.76 pp
XZO: +13.49% · LMRI: +78.25%
1Y Horizon LMRI +3.18 pp
XZO: -26.18% · LMRI: -23.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XZO vs LMRI. Trailing 12-month operating profitability (XZO 50.4% vs LMRI N/A) and valuation multiples (XZO 12.5x vs LMRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XZO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$233M
Gross Margin100.0%
Op. Margin50.4%
ROE / Fwd P/E46.7% · 12.5x
LMRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XZO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XZO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LMRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XZO Moat Profile High-Margin Pricing Power Moat
Insurance - Diversified Operator
Competes within the Insurance - Diversified value chain with $1.4B market capitalization and 50.4% operating margin.
OpEx & R&D Reinvestment 49.6% of Rev ($115M)
90D Engineering Disclosures 0 Published
LMRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XZO vs LMRI Key Questions & Quantitative Answers

As of Nov 20, 2026, Exzeo Group, Inc. (XZO) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XZO carries a Unified Composite Score of 47.7/100 (HOLD) at $14.72 (12.5x Forward P/E, 50.4% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin). Technically, XZO sits in a Neutral phase (RSI 34.6, UNCLASSIFIED options structure) and LMRI sits in a Markup phase (RSI 62.5, UNCLASSIFIED options structure).

XZO leads the Growth & Scale pillar: XZO posts +4.0% YoY revenue growth and -0.7% YoY earnings growth on $233M TTM revenue (100.0% gross margin, 50.4% operating margin), compared with LMRI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XZO generates $233M in USD-normalized revenue versus N/A for LMRI. In operating R&D and SG&A reinvestment, XZO deploys 49.6% of Rev ($115M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LMRI.

XZO screens cheaper on headline valuation multiples. XZO trades at 12.5x Forward P/E, 15.5x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (44.5% FCF margin), whereas LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XZO (46.7% ROE) versus LMRI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, XZO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.08β · 60% Vol realized risk). By comparison, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.